Analyst Ratings For NASDAQ:VTVT – vTv Therapeutics (NASDAQ:VTVT)
Today, NASDAQ:VTVT – vTv Therapeutics (NASDAQ:VTVT) stock was downgraded by Northland Securities from Outperform to Market Perform.
Some recent analyst ratings include
- 4/10/2018-Northland Securities was Downgraded by analysts at Northland Securities from a “Outperform ” rating to a ” Market Perform” rating.
- 4/10/2018-Seaport Global Securities was Downgraded by analysts at Seaport Global Securities from a “Buy ” rating to a ” Neutral” rating.
- 4/10/2018-Piper Jaffray was Downgraded by analysts at Piper Jaffray from a “Overweight ” rating to a ” Hold” rating. They now have a $4.00 price target on the stock.
- 4/10/2018-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating.
- 3/8/2018-Roth Capital initiated coverage with a Buy rating.
- 11/8/2017-Citigroup Reiterated Rating of add.
Recent Insider Trading Activity For NASDAQ:VTVT – vTv Therapeutics (NASDAQ:VTVT)
NASDAQ:VTVT – vTv Therapeutics (NASDAQ:VTVT) has insider ownership of 2.00% and institutional ownership of 11.20%.
- On 12/26/2017 Ronald O Perelman, Major Shareholder, bought 50,000 with an average share price of $4.03 per share and the total transaction amounting to $201,500.00.
- On 12/7/2017 Paul G Savas, Director, bought 15,000 with an average share price of $4.56 per share and the total transaction amounting to $68,400.00.
- On 8/22/2017 Ronald O Perelman, Major Shareholder, bought 20,000 with an average share price of $4.57 per share and the total transaction amounting to $91,400.00.
- On 8/16/2017 Ronald O Perelman, Major Shareholder, bought 10,000 with an average share price of $4.97 per share and the total transaction amounting to $49,700.00.
- On 8/15/2017 Ronald O Perelman, Major Shareholder, bought 50,000 with an average share price of $4.72 per share and the total transaction amounting to $236,000.00.
- On 8/11/2017 Ronald O Perelman, Major Shareholder, bought 85,000 with an average share price of $4.13 per share and the total transaction amounting to $351,050.00.
- On 5/15/2017 Paul G Savas, Director, bought 3,000 with an average share price of $5.18 per share and the total transaction amounting to $15,540.00.
Recent Trading Activity for NASDAQ:VTVT – vTv Therapeutics (NASDAQ:VTVT)
Shares of NASDAQ:VTVT – vTv Therapeutics closed the previous trading session at 0.97 down -2.29 70.25% with shares trading hands.